IDH1-R132H (mIDH1) catalyzes the production of 2-hrydroxyglutarate, eliciting epigenetic reprogramming of gene expression (33, 40, 43, 44) and is associated with better prognosis in glioma patients (33, 39, 40, 45). Here, IDH1 is linked to central nervous system cancer.